Clinical trial
Efficacy and Safety of Riociguat (MK-4836) in Incipient Pulmonary Vascular Disease as an Indicator for Early Pulmonary Arterial Hypertension Double-blind, Randomized, Multicenter, Multinational, Placebo-controlled Phase IIa Study (ESRA)
NCT05339087 is registered in ClinicalTrials.gov with Heidelberg University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Efficacy and Safety of Riociguat (MK-4836) in Incipient Pulmonary Vascular Disease as an Indicator for Early Pulmonary Arterial Hypertension Double-blind, Randomized, Multicenter, Multinational, Placebo-controlled Phase IIa Study (ESRA)
- Lead sponsor
- Heidelberg University
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- October 24, 2022
- Completion date
- July 31, 2025
- Enrollment
- 35 (actual)
- Sites
- 8
Conditions
As the registry lists them; a condition with its own page is linked.
other systemic involvement of connective tissue, primary pulmonary hypertension, pulmonary vascular disorder, systemic sclerosis